Abbott Laboratories (ABT) Other Accumulated Expenses (2009 - 2026)

Abbott Laboratories has disclosed Other Accumulated Expenses across 18 years of filings, most recently posting $6.9 billion for Q2 2026.

• In Q2 2026, Other Accumulated Expenses rose 21.85% year-over-year to $6.9 billion; the TTM figure through Jun 2026 stood at $6.9 billion (up 21.85% YoY), while the FY2025 annual figure was $5.8 billion, up 13.01% from the prior year.
• Other Accumulated Expenses came in at $6.9 billion for Q2 2026 at Abbott Laboratories, up from $6.4 billion in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $6.9 billion in Q2 2026 to a low of $5.1 billion in Q2 2024.
• Average Other Accumulated Expenses over 5 years is $5.6 billion, with a median of $5.5 billion recorded in 2022.
• Year-over-year, Other Accumulated Expenses dropped 9.34% in 2024 and climbed 21.85% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $5.8 billion in 2022, then slipped by 7.24% to $5.4 billion in 2023, then decreased by 5.15% to $5.1 billion in 2024, then gained by 13.01% to $5.8 billion in 2025, then climbed by 18.58% to $6.9 billion in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $6.9 billion in Q2 2026, $6.4 billion in Q1 2026, and $5.8 billion in Q4 2025.